Over the past 30 years, it has been shown that certain vanadium containing compounds have properties that enhance insulin in treatment of non insulin dependent diabetes mellitus (NIDDM). The research presented will focus on the development and characterization of heterocyclic tridentate ligands and their use in vanadium coordination complexes, which may subsequently be used as a possible NIDDM treatment. Tris[2-N-methylimidazolyl)] carbinol, (2-^MeTIC), is one such tridentate ligand. Co, Ni, and Cu coordination complexes of the general formula M(2-^MeTIC)₂X₂ (M=Co, Ni, Cu; X=Cl, NO₃) was used to study the binding and electronic effects of this ligand. The complexes were further characterized using X-ray diffraction, IR spectroscopy, UV/VIS spectroscopy, and ¹H NMR. Potential insulin enhancing V and (2-^MeTIC)-containing complexes have also been synthesized and characterized. These results will be presented here.